Who
Dylan Hartley
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, OnKure Therapeutics.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 Oct 2024
- Last trade
- 7 Aug 2026
- Last filed
- 11 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —137,603 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,603 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —137,603 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,603 | filing |
| 1 Apr 2026filed 3 Apr 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 27 Jan 2025filed 29 Jan 2025 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 4 Oct 2024filed 8 Oct 2024 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,603 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.